홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /반응

1-(Oxan-4-yl)piperazine → (R)-1-(2-dimethylamino-7-methyl-1H-benzimidazol-5-ylmethyl)-2-oxo-2-[4-(tetrahydropyran-4-yl)-piperazin-1-yl]-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

HRID 491110
인쇄

반응식

HRID 491110 반응식
[O:1]=[C:2]1[N:8]([CH:9]2[CH2:14][CH2:13][N:12]([C:15]([O:17][C@@H:18]([C:33]([OH:35])=O)[CH2:19][C:20]3[CH:31]=[C:30]([CH3:32])[C:23]4[NH:24][C:25]([N:27]([CH3:29])[CH3:28])=[N:26][C:22]=4[CH:21]=3)=[O:16])[CH2:11][CH2:10]2)[CH2:7][CH2:6][C:5]2[CH:36]=[CH:37][CH:38]=[CH:39][C:4]=2[NH:3]1.[O:40]1[CH2:45][CH2:44][CH:43]([N:46]2[CH2:51][CH2:50][NH:49][CH2:48][CH2:47]2)[CH2:42][CH2:41]1>>[O:1]=[C:2]1[N:8]([CH:9]2[CH2:10][CH2:11][N:12]([C:15]([O:17][C@H:18]([CH2:19][C:20]3[CH:31]=[C:30]([CH3:32])[C:23]4[NH:24][C:25]([N:27]([CH3:28])[CH3:29])=[N:26][C:22]=4[CH:21]=3)[C:33](=[O:35])[N:49]3[CH2:48][CH2:47][N:46]([CH:43]4[CH2:44][CH2:45][O:40][CH2:41][CH2:42]4)[CH2:51][CH2:50]3)=[O:16])[CH2:13][CH2:14]2)[CH2:7][CH2:6][C:5]2[CH:36]=[CH:37][CH:38]=[CH:39][C:4]=2[NH:3]1
참가 물질실험 절차출처 및 근거반응 노트

참가 물질

3

반응물 2

HCID 219423151-(Oxan-4-yl)piperazineHCID 178425373(R)-1-carboxy-2-(2-dimethylamino-7-methyl-1H-benzimidazol-5-yl)-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

생성물 1

HCID 178425371(R)-1-(2-dimethylamino-7-methyl-1H-benzimidazol-5-ylmethyl)-2-oxo-2-[4-(tetrahydropyran-4-yl)-piperazin-1-yl]-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate

실험 절차

Prepared analogously to Example 1h from 90 mg (0.14 mmol, purity 85%) (R)-1-carboxy-2-(2-dimethylamino-7-methyl-1H-benzimidazol-5-yl)-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate and 35 mg (0.21 mmol) 1-(tetrahydropyran-4-yl)-piperazine.

출처 및 근거

ORD 기록
ord-0e615e362b54433c8c6a9b9daf92a274
출처 데이터셋
uspto-grants-2009_05
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US07528129B2

반응 노트

이 페이지에서참가 물질실험 절차출처 및 근거반응 노트